^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    clofarabine

    i
    Other names: JC0707, Cl-F-ara-A, CAFdA, GZ-393590, SAR-393590
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    7d
    Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2026 --> Jul 2026
    Trial completion date
    |
    BRAF V600E • BRAF V600
    |
    clofarabine
    1m
    A Prospective Clinical Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia Induced by Clofarabine in Pediatric Patients with Langerhans Cell Histiocytosis (ChiCTR2500114943)
    P4, N=22, Not yet recruiting, West China Second University Hospital, Sichuan University; West China Second University Hospital, Sichuan University
    New P4 trial
    |
    clofarabine
    2ms
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (clinicaltrials.gov)
    P2, N=31, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
    4ms
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2025 --> Sep 2026
    Trial completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    sirolimus • clofarabine • melphalan
    4ms
    AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)
    P3, N=5949, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    6ms
    VyClo: Vyxeos® With Clofarabine for Pediatric AML (clinicaltrials.gov)
    P1, N=25, Recruiting, Princess Maxima Center for Pediatric Oncology
    New P1 trial
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • clofarabine
    6ms
    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 23 | Trial completion date: Apr 2027 --> Jul 2026 | Trial primary completion date: Oct 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)
    7ms
    NCI-2018-01198: Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia (clinicaltrials.gov)
    P2, N=42, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2025 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • bortezomib • cyclophosphamide • etoposide IV • clofarabine • Arzerra (ofatumumab) • Truxima (rituximab-abbs) • Marqibo (vincristine liposomal) • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    7ms
    Discovery of a novel non-toxic analog of clofarabine for the treatment of triple negative breast cancer. (PubMed, Bioorg Med Chem Lett)
    Our preliminary structure-activity relationship study resulted in the identification of analog 9 with enhanced activity against TNBC cells and improved cytotoxicity. One major advantage of analog 9 is that a pilot dose range finding study demonstrated that this analog elicited no signs of toxicity, whereas clofarabine was not well tolerated.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    clofarabine
    9ms
    Cross-Species Functional Genomic Screens Identify Novel Therapeutic Targets in Malignant Peripheral Nerve Sheath Tumors. (PubMed, Am J Pathol)
    Five druggable targets were selected for validation, with four of the five agents tested proving effective against human MPNST cells (the POLA1 inhibitor clofarabine, DNTT inhibitor cordycepin, BCL6 inhibitor 79-6 and LPAR1/3 inhibitor Ki16425). Clofarabine was especially effective, potently reducing cell numbers at low nanomolar concentrations and inducing a senescent phenotype, possibly via the p53/p21 pathway. These results demonstrate the utility of cross-species functional oncogenomics for the discovery of novel therapeutic targets relevant to human MPNSTs and suggest that clofarabine warrants further evaluation for its therapeutic potential.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6) • POLA1 (DNA Polymerase Alpha 1)
    |
    clofarabine • cordycepin (OVI-123)
    9ms
    Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children (clinicaltrials.gov)
    P2, N=20, Recruiting, West China Second University Hospital
    New P2 trial • Real-world evidence
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • clofarabine
    9ms
    A Multicenter Clinical Study of Clofarabine as Salvage Therapy in Children with Refractory/Relapsed Langerhans Cell Histiocytosis (ChiCTR2500102536)
    P4, N=66, Recruiting, Beijing Children's Hospital, Capital Medical University; Beijing Children's Hospital, Capital Medical University
    New P4 trial
    |
    clofarabine